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Abstract
Background: The purpose of this review is to examine the effect of Omega-3 Fatty acids on mortality, morbidity,
and adverse events in patients with acute myocardial infarction (AMI).
Methods: Data Sources: MEDLINE, EMBASE, and the Cochrane Library through May 2018. Study Selection:
Randomized Controlled trials (RCT). Certainty of evidence was assessed with the GRADE system. Interventions:
omega 3 fatty acids against placebo or no treatment. Primary and secondary outcomes: All-cause death,
cardiovascular death, new AMI, stroke, need for therapeutic angioplasty or By-pass, new diagnosis of cancer and
incidence of adverse events.
Results: For the efficacy endpoints we included 10 RCT (24,414 patients). Omega 3 fatty acids probably make little
or no difference to all-cause mortality (4 studies 9141 patients RR 1.06 - CI95% 0.90 to 1.27, moderate certainty),
cardiovascular mortality (3 studies 4304 patients RR 0.93 - CI95% 0.63 to 1.37, moderate certainty), new AMI (RR 1.24
CI95% 0.71 to 2.14 - moderate certainty), any cardiovascular event (RR 0.95 95%CI 0.86 to 1.05; low certainty due to
risk of bias and imprecision), and stroke (RR 1.2 95%CCI 0,66–2,19 - moderate certainty). Regarding adverse events,
we are uncertain if Omega 3 fatty acids improve/reduce non severe adverse events (RR 1.39 95% CI 0.36 to 5.34;
very low certainty). There is probably little or no difference in the outcome suspension due to adverse events (RR 1.
19 CI 95% 0.97 to 1.47; moderate certainty).
Conclusions: For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.
Keywords: Omega 3 fatty acid, Polyunsaturated fatty acids, Myocardial infarction, Secondary prevention, Systematic review
Background
n-3PUFAs are a family of polyunsaturated fatty acids,
named as such because of the positioning of the first
double carbon bond on the third atom from the methyl
end of the acyl chain. Dietary sources of Omega 3 include
certain nuts and seeds, such as walnuts, flaxseed and rape-
seed (canola) oil, fatty fish, some white fish, shellfish and
other seafood such as seaweed, and certain eggs and ani-
mal products, depending on the animal’s diet.
Proposed benefits of omega 3 fatty acids include low-
ering of blood pressure, reducing serum triglyceride con-
centration, increasing plaque stability and improving
endothelial function [1–4]. In the context of previous
acute myocardial infarction the mentioned omega 3 fatty
acids plaque stabilization properties could result in sig-
nificant benefits [4–7].
Multiple randomized controlled trials (RCT) evaluating
the efficacy and safety safety of fatty acids have been pub-
lished and their results summarized in different systematic
reviews. However those published analysis have important
limitations as we describe in the Additional file 1: Appendix
1. Furthermore, none of them performed a differential AMI
patients analysis. In this context, we consider that a new sys-
tematic review (SR) is justified. The present systematic
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review and meta-analysis aimed to improve estimations and
to assess whether dietary or supplemental omega 3 fatty
acids affects total or cardiovascular mortality in the context
of myocardial infarction secondary prevention.
Methods
This research is not a clinical trial and therefore does
not need to be registered.
Search strategy and elegibility criteria
We searched for randomized controlled trials comparing
omega 3 fatty acids against placebo or no treatment in the
following literature databases, regardless of publication
status and without language restrictions: the Cochrane
Central Register of Controlled Trials from the Cochrane
Library, MEDLINE, EMBASE, Epistemonikos and LI-
LACS from inception until May 2018.Details of the full
search strategies are provided in the Additional file 1:
Appendix 2. Our gray-literature search included searches
in Grey Matters Tool [8]. We also searched the Canadian
Agency for Drugs and Technology in Health, Google
Scholar, Trip Database, National Institute for Health and
Care Excellence, McMaster University, McMaster Health
Forum, PROSPERO, ClinicalTrials.gov, and manually ex-
amined the reference lists of all reviews identified.
As for the inclusion criteria, we included RCTs of
adults that suffered a myocardial infarction (according
to the study’s definition) and were randomized to receive
omega 3-fatty acid supplementation at doses greater
than or equal to 400 mg daily versus placebo/No treat-
ment. The treatment should have started within 6 weeks
after the initial diagnosis of the myocardial infarction.
We considered any mode of administration of the inter-
vention, such as dietary supplementation (fish oils, soya
bean oils, seeds, refined EPA, DHA, ALA) or, oil or cap-
sule form or as foodstuffs. To be eligible, studies had to
report at least one of the following outcomes: All-cause
death, cardiovascular death, new acute myocardial in-
farction, stroke, need for therapeutic angioplasty or
By-pass, new diagnosis of cancer and incidence of ad-
verse events.
Study selection and data extraction
Two investigators (G.B. and F.P.) independently
reviewed the titles and abstracts identified and full texts
of included articles in order to determine eligibility using
the EROS tool for systematic reviews early phases [9].
Disagreements or uncertainties were resolved by consen-
sus of the whole team with an additional investigator
(A.I.). We accepted the primary authors’ definition of
AMI, stroke, adverse event and serious adverse event.
The risk of bias was assessed independently by two re-
viewers on an outcome by outcome basis using a modifica-
tion of the Cochrane Risk of Bias Tool which considers,
sequence generation, allocation concealment, blinding,
number of patients with missing outcome data, selective
outcome reporting, and other sources of bias [10]. We used
the Grading of Recommendations Assessment, Develop-
ment and Evaluation system to assess the certainty of the
effect (also known as quality of evidence or confidence in
evidence) for each outcome and for the entire body of evi-
dence [11, 12]. Certainty of the effect takes into consider-
ation the study design (in this case, randomized clinical
trials); risk of bias, precision, consistency, directness of the
evidence; and the probability of publication bias [13].
Statistical analysis
We analyzed the data using Review Manager, version 5.3
(Cochrane Collaboration). We used random-effects
models for all analyses (Mantel–Haenszel risk ratios [RRs]
for dichotomous outcomes) since significant heterogeneity
was expected. Publication bias was assessed through visual
inspection of funnel plots (Additional file 1: Appendix 3)
and the subjective impression of the reviewers (G.B., F.P.
and A.I.) considering the size of the included studies and
sponsorship. We also contacted investigators to consult
whether they had knowledge of other potentially relevant
unpublished trials.
We used Cochrane’s test for heterogeneity to deter-
mine whether studies in a meta-analysis evaluated the
same underlying sizes of effect. We used the I2 statistic
to test the degree of heterogeneity among studies (the
proportion of total observed variability due to genuine
variation rather than random error within studies) [14].
We planned a priori the following subgroup analyses
as possible explanations for heterogeneity: 1) type of
fatty acid: eicosapentaenoic acid and docosahexaenoic
acid versus alpha-linolenic acids with a postulated larger
effect for the latter [9, 15]; 2) Dose effect: high dose
(consumption of more than 4.5 g daily) of Omega 3 fatty
acids could be associated with a larger treatment benefit;
3) Type of omega 3: synthetic omega 3 (in comparison
with dietary recommendations with increased omega 3
fatty acid intake) could be associated with a larger treat-
ment benefit; 4) Risk of bias: Studies with high risk of
bias could be associated with a larger treatment benefit.
We visually analyzed the results of each subgroup com-
parison and additionally tested for interaction by using a
chi-square significance test [14].
Dealing with missing data
For the primary analysis we used a complete case-analysis
approach, i.e. we excluded participants considered to have
missing data. For those outcomes in which a clinically sig-
nificant effect was observed (Relative risk CI95% not in-
cluding 1), we performed a sensitivity analysis to challenge
the possibility of risk of bias due to missing data following
the approach described by Guyatt et.al [16, 17] (complete
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description of the implemented sensitivity analysis is avail-
able in Additional file 1: Appendix 4).
Patient and public involvement
Patients were not involved in this review.
Results
Study characteristics
We identified 610 potentially relevant records. After
screening titles, abstracts and full texts we included 11
publications for quantitative analysis (Fig. 1.).
The characteristics of the 11 RCTs included are sum-
marized in Table 1. In six [18–23] of them the interven-
tion was implemented in the form of dietary
recommendations while EDH-EPA (synthetic form of
omega 3 fatty acids) was implemented in the remaining
four [24–28].
Risk-of-Bias assessment
In five of the included studies [18, 22, 25–28], patients,
investigators and outcome assessors were blinded. Four
of those studies were judged as low risk of bias as no
additional methodological issues were noted. Regard-
ing the remaining studies, six were judged as to carry
moderate or high risk of bias (Fig. 2). Although one of
the included studies had no apparent methodological
limitations, we decided to judge it as high risk of bias
[27] because the author was accused of misconduct and
data fabrication in two different trials in which he was
involved [30, 31]. We assumed the trials to have import-
ant lost to follow-up when the authors did not offer
enough information to analyze the impact of missing
data or if the performed sensitivity analysis significantly
altered the effect estimate or the confidence interval for
each outcome. (Additional file 1: Appendix 4).
All-cause mortality
All the included trials addressed this outcome. Omega 3
fatty acids reduced the risk of all-cause mortality (RR
0.86, CI 95% 0.72 to 1.02). Considering the basal risk
(risk without the intervention) as the mean of the risk in
the control groups of the included RCT, the mortality
reduction was 1.4% (CI95% 2.5 to 0) at a mean follow up
of 3 years. We judged the certainty in the estimates of
Fig. 1 Flow chart of study selection









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Popoff et al. BMC Cardiovascular Disorders          (2019) 19:136 Page 4 of 13
effect as low due to risk of bias, imprecision and incon-
sistency (I2 85%) (Fig. 3), (Table 2).
Cardiovascular mortality
Nine of the included trials addressed this outcome.
Omega 3 fatty acids reduced the risk of cardiovascular
mortality (RR 0.77, CI 95% 0.65 to 0.91). Considering
the basal risk as the mean of the risk in the control
groups of the included RCT, the cardiovascular mortality
reduction was 1.5% (CI95% 2.3 to 0.6) at a mean follow
up of approximately 3 years. We judged the certainty in
the estimates of effect as low due to risk of bias and in-
consistency (Fig. 4), (Table 2).
Acute myocardial infarction
Seven of the included trials addressed this outcome.
Omega 3 fatty acids reduced the risk of Myocardial in-
farction (RR 0.77, CI 95% 0.6 to 0.99). Considering the
basal risk as the mean of the risk in the control groups
of the included RCT, the cardiovascular mortality reduc-
tion was 2.2% (CI95% 3.8 to 0.1) at a mean follow up of
approximately 3 years. We judged the certainty in the es-
timates of effect as low due to risk of bias, imprecision
and inconsistency) (Fig. 5), (Table 2).
Stroke
Five of the included trials addressed this outcome.
Omega 3 fatty acids did not reduce the risk of stroke
(RR 1.2, CI 95% 0.66 to 2.19). Considering the basal risk
as the mean of the risk in the control groups of the in-
cluded RCT a marginal increase in the risk of stroke was
observed RD 0.2% (CI95% -0.4 to 1.4%) at a mean follow
up of approximately 3 years. We judged the certainty in
the estimates of effect as moderate due to imprecision
(Fig. 6), (Table 2).
Need to therapeutic revascularization
Three of the included trials addressed this outcome.
Omega 3 fatty acids did not reduce the risk of thera-
peutic revascularization (RR 1.0 CI 95% 0.91). Consider-
ing the basal risk as the mean of the risk in the control
groups of the included RCT no differences in the need
of therapeutic revascularization were observed RD 0%
(CI95% -1.9 to 2.4%) at a mean follow up of approximately
3 years. We judged the certainty in the estimates of effect
as moderate due to imprecision (Fig. 7), (Table 2).
Treatment suspension due to adverse events
Two of the included trials addressed this outcome.
Omega 3 fatty acids increased the relative risk of treat-
ment suspension due to adverse effects (RR 1.19 CI 95%
0.97 to 1.47). Considering the basal risk as the mean of
the risk in the control groups of the included RCT no
differences in the risk of treatment suspension due to
adverse effects was observed RD 0.3% (CI95% -0.1 to
0.7%) at a mean follow up of approximately 3 years. We
judged the certainty in the estimates of effect as moder-
ate due to imprecision (Fig. 8), (Table 2).
Cancer
Two of the included trials addressed this outcome.
Omega 3 fatty acids increased the relative risk of cancer
(RR 1.25 CI 95% 0.94 to 1.66). Considering the basal risk
as the mean of the risk in the control groups of the in-
cluded RCT only a marginal increase in cancer occurrence
was observed RD 0.3% (CI95% -0.1 to 0.7%) at a mean fol-
low up of approximately 3 years. We judged the certainty
in the estimates of effect as very low due to imprecision
Fig. 2 Risk-of-Bias of included studies
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and indirectness (Fig. 9). The results are shown in a Sum-
mary of Finding Table (Table 2).
Subgroup analysis
Inconsistency was observed for overall mortality, cardio-
vascular mortality and myocardial infarction outcomes.
In performing the prespecified risk of bias subgroup
analysis we observed that the benefits (mortality, cardio-
vascular mortality and MI reduction), suggested by the
overall pooled results, were not present when pooling
the subgroup of studies in which the intervention was
applied in a blinded fashion (low risk of bias). Although
the test for subgroup differences was only statistically
significant for overall mortality (p < 0.05) visual inspec-
tion of the forest plots suggest a similar subgroup effect
for the three outcomes. The Fatty acid type subgroup
analysis also showed a possible differential effect (less
cardiovascular mortality) when EPA-DHA was imple-
mented in comparison to ALA (RR 0.66, IC95% 0.35–
1.27 for ALA vs. RR 0.82, IC95% 0.72–094) for EPA +
DHA. No significant differences were observed when
different doses were used.
We then decided to include, in the summary of find-
ings tables, both the results of the overall pooled esti-
mates and the results of the blinded trials pooled
estimates (Table 2). We used primarily a 4 mg threshold
to evaluate the effect of the dose of omega 3 fatty acid
which showed no effect on the evaluated outcomes. A
secondary analysis using a 1 mg threshold showed also
no impact on those outcomes.
Discussion
This systematic review provides moderate quality of evi-
dence that Omega 3 fatty acids do not significantly re-
duce mortality or major vascular events in patients with
acute myocardial infarction. Although the overall esti-
mates of effects analysis suggested a reduction in mortal-
ity and AMI recurrence, based on the results of the
subgroup analysis we consider that this finding is prob-
ably biased. Hence our main conclusions are based in
the pooled estimates provided by the blinded RCT (low
risk of bias subgroup). Nevertheless, we decided to re-
port both estimates (overall and low risk of bias sub-
group) in order to supply decision makers with all the
information (see Table 2). Regarding adverse events, par-
ticular concern has been raised by the possibility that
the intervention could cause cancer. This hypothesis was
drawn based on the observation that omega-3 fats cap-
sules could contain high levels of various toxic com-
pounds such as mercury, polychlorinated biphenyl and
dioxins [32–37]. Our results provide very low quality of
evidence suggesting that omega 3 may increase the risk
of cancer but the scarce number of events and the lim-
ited time of follow up make it difficult to draw definite
Fig. 3 Forest plot of comparison: Omega 3 vs. Placebo, outcome: 1.1 All-cause mortality - Risk of bias subgroup
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Fig. 5 Forest plot of comparison: Omega 3 vs. Placebo, outcome: 1.3 Acute myocardial infarction- Risk of bias subgroup
Fig. 4 Forest plot of comparison: Omega 3 vs. Placebo, outcome: 1.2 Cardiovascular mortality - Risk of bias subgroup
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conclusions regarding this outcome. This information,
consistent with the conclusions of other systematic re-
views on the topic [38–40], can help decision makers by
supporting the fact that the risk of significant negative ef-
fects related to omega 3 fatty acids cannot be ruled out.
Even though we observed a possible subgroup effect in
favor of DHA-EPA fatty acids, this is mainly based in
differences between studies, as opposed to differences in
subgroups within studies, and the differential effect was
mainly influenced by moderate/high risk of bias trials.
We consider that a true subgroup effect under these
conditions is unlikely.
Our review has limitations,. Although we performed
a thorough evidence search, we did not explored con-
ference abstracts. Besides we did not include studies
that randomized patients with AMI combined with
other subpopulations (i.e patients with stroke) [41] as
we could not gain access to individual patients’ data
or AMI subgroup results for any of those identified
trials [42, 43].
Fig. 6 Forest plot of comparison: Omega 3 vs. Placebo, outcome: 1.4 Stroke - Risk of bias subgroup
Fig. 7 Forest plot of comparison: Omega 3 vs. Placebo, outcome: 1.5 Need to revascularization - Risk of bias subgroup
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Although we understand that we could have missed
relevant information as a consequence of the mentioned
limitations, we consider that improbable. Our systematic
review has also particular strengths. First, it provides the
most comprehensive and trustworthy body of evidence
up to date, including studies that were not included in
other recent prior [19, 20, 22, 23, 28] reviews. While the
conclusions of our systematic review in terms of the ef-
fects of the intervention are not different from the con-
clusions of some of the published reviews addressing
similar questions, we believe that the analysis of the cer-
tainty of the evidence and the way in which we pre-
sented the results (following the GRADE approach)
better reflects the trustworthiness of the information
available, particularly regarding the absence of benefits
in terms of mortality reduction and AMI recurrence.
As mentioned in the introduction, none of the pub-
lished reviews on the topic, particularly the recently
published Cochrane review [44], performed a complete
and in-depth analysis of the effects of Omega 3 fatty
acids on the population of patients with acute myocar-
dial infarction. The most relevant differences of those SR
with ours comprise: 1) None included all the available
evidence [32, 44–46]; 2) Most did not perform a sub-
group analysis considering the risk of bias of the in-
cluded studies, which we believe, that in this particular
scenario, is crucial to interpret the whole body of evi-
dence [33, 46]; 3) Most included patients with cardiovas-
cular risk factors, stable angina pectoris or other
cardiovascular conditions but without previous events;
whereas we focused our question on the group of pa-
tients with acute myocardial infarction hypothesizing
that the Ingestion of omega-3 PUFAs including EPA and
DHA may result in more significant benefits by attenuat-
ing the inflammatory response triggered by the myocar-
dial injury [33, 44, 45].
The results and conclusions of those published re-
views are inconsistent. While some report a positive
effect of omega 3 fatty acids and even recommend its
use [47], others claim that there is not enough evi-
dence about the benefits of the intervention [44, 45].
One of the most recent reviews, published by Aung
et al. [48], deserves a detailed description. Although
the authors appropriately analyzed the results consid-
ering the risk of bias of the primary studies, they
failed to include most of the evidence related to
patients with previous MI (9 of 11 studies) [19–27],
see Additional file 1: Appendix 1). The authors con-
cluded that omega-3 fatty acids had no significant as-
sociation with fatal or nonfatal coronary heart disease
or any major vascular events. Similar considerations
can be made regarding the Cochrane review [44]. Our
results strengthen the ones seen in the reviews of
Cochrane and Aung by expanding their findings to
the high-risk subgroup of patients with previous MI.
Conclusion
Omega 3 fatty acid supplementation probably yields no
benefit to patient important outcomes for individuals
with previous AMI. The results of our systematic review
would provide useful information to panels aiming to
elaborate recommendations for the management of pa-
tients with previous AMI.
Fig. 8 Forest plot of comparison: Treatment suspension due to adverse events
Fig. 9 Forest plot of comparison: Cancer
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Strengths and limitations of this study
– The present systematic review provides estimations
regarding the efficacy of supplemental omega 3 fatty
acids in the context of myocardial infarction
secondary prevention paying special attention to the
risk of bias of the included studies
– Unlike most of the published reviews we focused in
the population of patients that had suffered an acute
myocardial infarction
– It provides the most comprehensive and trustworthy
body of evidence up to date, including studies not
included in any other published reviews [19, 20, 22,
23, 28].
– We performed a thorough analysis of the
information and identified significant differences in
the results of the primary studies that could be
explained by methodological limitations in some of
them.
Additional file
Additional file 1: Appendix 1. Recently published relevant systematic
reviews evaluating the intervention. Appendix 2. Details of the full search
strategies. Appendix 3. Funnel plot of the All-cause mortality comparison.
Appendix 4. Missing Outcome Data – Sensitivity analyses. (DOCX 106 kb)
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